Panel Discussion:: The Differentiating Debate: On-The-Shelf vs Off-The Shelf

Time: 9:00 am
day: Day Two


  • Dissecting the current state of accessibility
  • What roles separate antibody-based and cell-based therapies – can they all live together?
  • Discussing manufacturing production capabilities and scaling predictions for CAR-T: academic centers and community hospitals
  • Exploring pricing: can profitability be demonstrated?
  • Europe vs US vs global
  • Understanding age group considerations
  • How can we ensure timely CAR-T slot availability for patients in need? (Future of off-the shelf CAR-T’s or manufacturing changes?)
  • What clinical timelines are predicted: combinations, lines of therapy? What is the end goal?
  • How can we contextualize this in the competitive landscape? Competitive differentiation?